Home/Pipeline/ORN-101 (via Orna partnership)

ORN-101 (via Orna partnership)

CD19+ malignancies

Preclinical/Phase 1Active

Key Facts

Indication

CD19+ malignancies

Phase

Preclinical/Phase 1

Status

Active

Company

Simnova Biotherapeutics

About Simnova Biotherapeutics

Clinical-stage biotech developing off-the-shelf CAR-NK and BiTE CAR-T therapies for cancer treatment.

View full company profile

Therapeutic Areas